AndrzejJJakubowiakMD

Oncology • Chicago, IL

Hematologic Oncology

Professor, Medicine, University of Chicago Div of the Bio Sci The Pritzker SOM

Join to view full profile

Dr. Jakubowiak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jakubowiak's full profile

Already have an account?

Office
5841 S Maryland Ave
Chicago, IL 60637
Phone+1 888-824-0200

Fax+1 773-702-9268

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1994 - 1997
University of Texas Health Science Center at HoustonResidency, Pathology-Anatomic and Clinical, 1992 - 1992
University of Medical Science PoznanClass of 1977

Certifications & Licensure

IL State Medical License 2011 - 2026
NC State Medical License 2021 - 2022
MI State Medical License 2000 - 2013
NY State Medical License 1997 - 2000

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma Start of enrollment: 2005 Apr 01
Terminated
Phase 2
Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma Start of enrollment: 2005 Jun 01
Completed
Phase 2
Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma Start of enrollment: 2004 Jul 01
Completed
Not Applicable
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma Start of enrollment: 2005 Aug 01
Active, not recruiting
Phase 2
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma Start of enrollment: 2006 Dec 01
Completed
Phase 1
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2012 Apr 25
Completed
Phase 1
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 Aug 13
Recruiting
Phase 1, Phase 2
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma Start of enrollment: 2012 Sep 01
Terminated
Phase 1, Phase 2
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2013 Jan 01
Active, not recruiting
Phase 2
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2014 Jun 12
Recruiting
Phase 1
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma Start of enrollment: 2016 Apr 26
Active, not recruiting
Phase 3
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma Start of enrollment: 2017 Jul 10
Active, not recruiting
Phase 2
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Start of enrollment: 2019 Feb 13
Recruiting
Phase 2
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) Start of enrollment: 2019 May 07
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma.
Marcus Marable, Kaitlin Kelly, Jennifer H Cooperrider, Andrzej Jakubowiak, Benjamin A Derman
Ejhaem. 2024-12-01
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed mul...
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves
Future Oncology. 2024-10-25
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).
Benjamin A Derman, Ajay Major, Jennifer Cooperrider, Ken Jiang, Aubrianna Ramsland
Blood Cancer Journal. 2024-10-07

Abstracts/Posters

Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Andrzej Jakubowiak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)_CD3 Bispecific Antibody, in P...
Andrzej Jakubowiak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Andrzej Jakubowiak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)Clinically Releva...
Andrzej Jakubowiak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...
Andrzej Jakubowiak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refr...
Andrzej Jakubowiak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Anal...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaDecember 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaDecember 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaDecember 2017

Press Mentions

Triple Drug Combo Beats Single Therapy in Multiple Myeloma MaintenanceJanuary 25th, 2023
Triple-Drug Therapy for Post-Transplant Management of Multiple MyelomaJanuary 13th, 2023
Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022
Join now to see all